ClinicalTrials.gg
Status unknownNCT00017992Updated Jun 24, 2005

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

A Phase 2 interventional study of Lopinavir/Ritonavir and Emtricitabine in HIV Infections, sponsored by Triangle Pharmaceuticals. Status unknown at 14 sites in 6 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Triangle Pharmaceuticals · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2003), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Ages
3 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies testing emtricitabine in HIV Infections — 4 open to participants now, 8 under way, 4 of them phase 3. Emtricitabine · HIV Infections.

Enrollment
31st of 63
100 · median 100
Phase 2
11 of 65
none open now
Registered
5th of 65
by date
Lead sponsor
3 of 65
Triangle Pharmaceuticals

Among the 65 studies testing emtricitabine in HIV Infections, this one is the 31st largest by enrollment of the 63 interventional ones that give a count, is one of 11 in phase 2, and was the 5th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 65 studies testing emtricitabine in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About emtricitabine

Emtricitabine: first FDA approval 2003 (EMTRIVA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 3 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing emtricitabine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to see if emtricitabine is safe in children infected with HIV and to determine the best dose.

Read the detailed description

Children are placed into 1 of 4 treatment groups based on age: Group 1, 3 months to 24 months; Group 2, 25 months to 6 years; Group 3, 7 years to 12 years; Group 4, 13 years to 17 years. They receive baseline evaluations. Antiretroviral-naive patients receive emtricitabine plus stavudine plus lopinavir/ritonavir. Antiretroviral-experienced patients replace lamivudine with emtricitabine. Patients return to the clinic for follow-up visits at Weeks 2 and 4 and then every 4 weeks until Week 48. Safety is evaluated using adverse events, which are reviewed at every clinic visit. Clinical laboratory data and full-profile pharmacokinetics of emtricitabine are evaluated at some visits. After the Week 48 study evaluations are completed, individual patients may continue to receive study medication (as provided by the sponsor) until commercially available, if certain criteria are met.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Administration Schedule
  • Stavudine
  • HIV Protease Inhibitors
  • Ritonavir
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Pharmacokinetics
  • ABT 378
  • emtricitabine
04

Who can participate

Ages eligible
3 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Children may be eligible for this study if they:

  • Are at least 3 months old and no older than 17 years of age. This is the age the child needs to be at the time they begin the study.
  • Are positive.
  • Weigh more than 5.5 pounds. A newborn child must have reached at least 38 weeks of gestation.
  • Have or have not taken anti-HIV drugs. Those that have not must have a viral load between 5,000 and 500,000 copies/ml at screening. Those that have must have been taking anti-HIV drugs, including lamivudine, for at least 3 months and have a viral load of no more than 400 copies/ml at screening.
  • Have a of more than 200 cells/mm3.
  • Have written consent from parent or guardian.
  • Are willing to use effective during the study and for 1 month after the last dose of emtricitabine, if sexually active.

Exclusion criteria

Exclusion Criteria

Children will not be eligible for this study if they:

  • Are pregnant or breast-feeding.
  • Cannot follow the visit or dosing schedule or are not available for 1 year.
  • Have taken experimental drugs or vaccines (except for emivirine and experimental forms of approved drugs) within 30 days of study start.
  • Have nerve damage in their arms or legs.
  • Have trouble eating or taking drugs.
  • Have serious diarrhea within 30 days before study entry.
  • Have had any serious illness within 30 days of study screening. Any treatment must have been finished 14 days before study entry.
  • Have had an AIDS-related (opportunistic) disease within 12 months of screening.
  • Are being treated for tuberculosis.
  • Have had pancreatitis.
  • Require certain drugs.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Enrollment
100 participants

Interventions

06

Study locations

2 of 14 sites recruiting
  • USC School of Medicine / LA County Med Ctr
    Los Angeles, California 90033, United States
    Active, not recruiting
  • Univ of Florida Health Science Ctr / Pediatrics
    Jacksonville, Florida 32209, United States
    Active, not recruiting
  • Univ of Miami
    Miami, Florida 331016960, United States
    Active, not recruiting
  • Bronx Municipal Hosp Ctr/Jacobi Med Ctr
    Bronx, New York 10461, United States
    Active, not recruiting
  • New York Hosp / Cornell Med Ctr
    New York, New York 10021, United States
    Active, not recruiting
  • St Luke's - Roosevelt Hosp Ctr
    New York, New York 10025, United States
    Active, not recruiting
  • State Univ of New York at Stony Brook
    Stony Brook, New York 117948111, United States
    Active, not recruiting
  • Saint Jude Children's Research Hosp of Memphis
    Memphis, Tennessee 381052794, United States
    Active, not recruiting
  • Fundacion HUES
    Buenos Aires, Argentina
    Active, not recruiting
  • Instituto Mexicano de Investigacion Clinica
    Col Roma, Mexico
    Active, not recruiting
  • Hospital del Nino
    Panama City, Panama
    Active, not recruiting
  • Univ of Puerto Rico / Med Science Campus
    San Juan, 00936, Puerto Rico
    Active, not recruiting
  • Perinatal HIV Research UNIT
    Diepkloof, South Africa
    Recruiting
  • Infectious Diseases Clinincal Trial Unit
    Gaunteng, South Africa
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00017992
Lead sponsor
Triangle Pharmaceuticals
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2003. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emtricitabine

Start the discussion